Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	Unknown
Gender:	Female
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	00/00/0000 00:00

CYP3A4 and CYP3A5
ARUP test code 3001518

3A4/3A5 Specimen	Whole Blood
CYP3A4 Genotype	*1/*1A
CYP3A4 Phenotype	Normal
CYP3A5 Genotype	*1/*3
CYP3A5 Phenotype	**Intermediate** *

3A4/3A5 Interpretation

See Note

The following CYP3A4 allele(s) were detected: *1/*1A. This result predicts the normal metabolizer phenotype.

The following CYP3A5 allele(s) were detected: *1/*3. This result predicts the intermediate metabolizer phenotype.

Recommendation: Guidelines for genotype-based dosing are published by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and can be found at: https://cpicpgx.org/ and https://www.pharmgkb.org/.

This result has been reviewed and approved by ███████████ ████████

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 23-316-101110
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 1 of 3 | Printed: 11/27/2023 2:41:21 PM
4848

BACKGROUND INFORMATION: CYP3A4 and CYP3A5

CHARACTERISTICS: The cytochrome P450 (CYP) 3A subfamily of enzymes is involved in metabolism of many drugs. Variants in the genes that code for CYP3A4 and CYP3A5 may influence pharmacokinetics of CYP3A substrates, and may predict or explain non-standard dose requirements, therapeutic failure or adverse reactions.
INHERITANCE: Autosomal codominant.
CAUSE: CYP3A4 or CYP3A5 gene variants affect enzyme function.
VARIANTS TESTED:
(Variants are numbered according to NM_017460 transcript for CYP3A4 and NM_000777 transcript for CYP3A5)

*1: Indicative of no detected targeted variants and an assumption of functional allele.

CYP3A4*1A: rs2740574, c.-392G>A
CYP3A4*22: rs35599367, c.522-191C>T

CYP3A5*3: rs776746, c.219-237A>G
CYP3A5*6: rs10264272, c.624G>A
CYP3A5*7: rs41303343, c.1035dup

CLINICAL SENSITIVITY: Drug-dependent.
METHODOLOGY: Polymerase chain reaction (PCR) and fluorescence monitoring.
ANALYTICAL SENSITIVITY AND SPECIFICITY: Greater than 99 percent.
LIMITATIONS: Only the targeted CYP3A4 and CYP3A5 variants will be detected by this panel, and assumptions about phase and content are made to assign alleles. Publicly available sources such as the www.pharmvar.org or www.pharmgkb.org provide guidance on phenotype predictions and allele frequencies. Diagnostic errors can occur due to rare sequence variations. Risk of therapeutic failure or adverse reactions with CYP3A substrates may be affected by genetic and non-genetic factors that are not detected by this test. This result does not replace the need for therapeutic drug or clinical monitoring.

Please note the information contained in this report does not contain medication recommendations, and should not be interpreted as recommending any specific medications. Any dosage adjustments or other changes to medications should be evaluated in consultation with a medical provider.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

EER CYP3A4 CYP3A5   See Note

Authorized individuals can access the ARUP Enhanced Report using the following link:

H=High, L=Low, *=Abnormal, C=Critical

Patient: Patient, Example
ARUP Accession: 23-316-101110
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 2 of 3 | Printed: 11/27/2023 2:41:21 PM
4848

ARUP LABORATORIES
800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Chief Medical Officer

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
3A4/3A5 Specimen	23-316-101110	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CYP3A4 Genotype	23-316-101110	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CYP3A4 Phenotype	23-316-101110	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CYP3A5 Genotype	23-316-101110	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CYP3A5 Phenotype	23-316-101110	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
3A4/3A5 Interpretation	23-316-101110	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
EER CYP3A4 CYP3A5	23-316-101110	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Patient: Patient, Example
ARUP Accession: 23-316-101110
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 3 of 3 | Printed: 11/27/2023 2:41:21 PM
4848